Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PEPD | P12955 | 1/20 | 0.44 |
| ▸ | IMPDH2 | P12268 | 3/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | CCR2 | P41597 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30987654 | 1.00 | PEPD (0.44) | PEPDIMPDH2PTPN1HDAC8NR1H2 | |
| SCHEMBL15660593 | 1.00 | PEPD (0.44) | PEPDIMPDH2PTPN1HDAC8NR1H2 | |
| SCHEMBL27274306 | 0.94 | PEPD (0.49) | PEPDIMPDH2PTPN1HDAC8NR1H2 | |
| SCHEMBL12773345 | 0.94 | PEPD (0.49) | PEPDIMPDH2PTPN1HDAC8NR1H2 | |
| SCHEMBL13859052 | 0.94 | PEPD (0.49) | PEPDIMPDH2PTPN1HDAC8NR1H2 | |
| SCHEMBL12604939 | 0.92 | HSD17B10 (0.36) | PEPDIMPDH2HDAC8NR1I2HSD17B10 | |
| SCHEMBL10138525 | 0.92 | HSD17B10 (0.36) | PEPDIMPDH2HDAC8NR1I2HSD17B10 | |
| SCHEMBL30749399 | 0.88 | PEPD (0.42) | PEPDIMPDH2PTPN1HDAC8NR1H2 | |
| Hydrochloric Acid SCHEMBL27225687 | 0.87 | PEPD (0.41) | PEPDIMPDH2PTPN1HDAC8NR1H2 | |
| SCHEMBL12604940 | 0.86 | HSD17B10 (0.42) | HDAC8NR1I2HSD17B10LMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2912031-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-05-31 | — | — | EP | disclosed |
| US-9561212-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-02-07 | — | — | US | disclosed |
| US-20160338999-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-24 | — | — | US | disclosed |
| US-20150252028-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-09-10 | — | — | US | disclosed |
| EP-2912031-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2015-09-02 | — | — | EP | disclosed |
| WO-2014065791-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160338999-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | PEPD 1912/4885IMPDH2 1225/4885PTPN1 1524/4885 |
| US-20150252028-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | PEPD 1912/4885IMPDH2 1225/4885PTPN1 1524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.